These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 8171739

  • 1. Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status.
    Lissoni P, Brivio F, Ardizzoia A, Tancini G, Barni S.
    Tumori; 1993 Dec 31; 79(6):401-4. PubMed ID: 8171739
    [Abstract] [Full Text] [Related]

  • 2. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
    Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, Brivio F, Tisi E, Rovelli F, Rescaldani R.
    Br J Cancer; 1994 Jan 31; 69(1):196-9. PubMed ID: 8286206
    [Abstract] [Full Text] [Related]

  • 3. Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results.
    Lissoni P, Barni S, Rovelli F, Brivio F, Ardizzoia A, Tancini G, Conti A, Maestroni GJ.
    Eur J Cancer; 1993 Jan 31; 29A(2):185-9. PubMed ID: 8422280
    [Abstract] [Full Text] [Related]

  • 4. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P, Bolis S, Brivio F, Fumagalli L.
    Anticancer Res; 2000 Jan 31; 20(3B):2103-5. PubMed ID: 10928160
    [Abstract] [Full Text] [Related]

  • 5. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, Fumagalli L, Bordoni A, Mengo S, Gardani GS, Tancini G.
    In Vivo; 2002 Jan 31; 16(2):93-6. PubMed ID: 12073777
    [Abstract] [Full Text] [Related]

  • 6. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
    Lissoni P, Barni S, Tancini G, Mainini E, Piglia F, Maestroni GJ, Lewinski A.
    Oncology; 1995 Jan 31; 52(2):163-6. PubMed ID: 7854778
    [Abstract] [Full Text] [Related]

  • 7. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates.
    Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Meregalli S, Fossati V, Fumagalli L, Brivio F, Tancini G.
    Oncology; 1995 Jan 31; 52(3):243-5. PubMed ID: 7715908
    [Abstract] [Full Text] [Related]

  • 8. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
    Lissoni P, Brivio F, Brivio O, Fumagalli L, Gramazio F, Rossi M, Emanuelli G, Alderi G, Lavorato F.
    J Biol Regul Homeost Agents; 1995 Jan 31; 9(1):31-3. PubMed ID: 8553906
    [Abstract] [Full Text] [Related]

  • 9. Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
    Lissoni P, Barni S, Tancini G, Ardizzoia A, Rovelli F, Cazzaniga M, Brivio F, Piperno A, Aldeghi R, Fossati D.
    Br J Cancer; 1993 Jun 31; 67(6):1404-7. PubMed ID: 8512825
    [Abstract] [Full Text] [Related]

  • 10. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma.
    Aldeghi R, Lissoni P, Barni S, Ardizzoia A, Tancini G, Piperno A, Pozzi M, Ricci G, Conti A, Maestroni GJ.
    Eur J Cancer; 1994 Jun 31; 30A(2):167-70. PubMed ID: 8155391
    [Abstract] [Full Text] [Related]

  • 11. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
    Lissoni P, Tisi E, Barni S, Ardizzoia A, Rovelli F, Rescaldani R, Ballabio D, Benenti C, Angeli M, Tancini G.
    Br J Cancer; 1992 Jul 31; 66(1):155-8. PubMed ID: 1322155
    [Abstract] [Full Text] [Related]

  • 12. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
    Lissoni P, Fumagalli L, Paolorossi F, Rovelli F, Roselli MG, Maestroni GJ.
    J Biol Regul Homeost Agents; 1997 Jul 31; 11(3):119-22. PubMed ID: 9498162
    [Abstract] [Full Text] [Related]

  • 13. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer.
    Lissoni P, Meregalli S, Fossati V, Paolorossi F, Barni S, Tancini G, Frigerio F.
    Tumori; 1994 Dec 31; 80(6):464-7. PubMed ID: 7900237
    [Abstract] [Full Text] [Related]

  • 14. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.
    Lissoni P, Barni S, Fossati V, Ardizzoia A, Cazzaniga M, Tancini G, Frigerio F.
    Support Care Cancer; 1995 May 31; 3(3):194-7. PubMed ID: 7655780
    [Abstract] [Full Text] [Related]

  • 15. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
    Lissoni P, Malugani F, Malysheva O, Kozlov V, Laudon M, Conti A, Maestroni G.
    Neuro Endocrinol Lett; 2002 Aug 31; 23(4):341-4. PubMed ID: 12195238
    [Abstract] [Full Text] [Related]

  • 16. A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia.
    Lissoni P, Barni S, Brivio F, Rossini F, Fumagalli L, Ardizzoia A, Tancini G.
    Oncology; 1995 Aug 31; 52(5):360-2. PubMed ID: 7637951
    [Abstract] [Full Text] [Related]

  • 17. Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma.
    Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Paolorossi F, Brivio F, Perego M, Tancini G, Conti A, Maestroni G.
    Tumori; 1992 Dec 31; 78(6):383-7. PubMed ID: 1297233
    [Abstract] [Full Text] [Related]

  • 18. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
    Lissoni P, Barni S, Ardizzoia A, Olivini G, Brivio F, Tisi E, Tancini G, Characiejus D, Kothari L.
    J Biol Regul Homeost Agents; 1993 Dec 31; 7(4):121-5. PubMed ID: 8023699
    [Abstract] [Full Text] [Related]

  • 19. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
    Lissoni P, Mandalà M, Brivio F.
    Eur Urol; 2000 Jul 31; 38(1):115-8. PubMed ID: 10859453
    [Abstract] [Full Text] [Related]

  • 20. Immunotherapy with subcutaneous low dose interleukin-2 plus melatonin as salvage therapy of heavily chemotherapy-pretreated ovarian cancer.
    Lissoni P, Ardizzoia A, Barni S, Tancini G, Muttini M.
    Oncol Rep; 1996 Sep 31; 3(5):947-9. PubMed ID: 21594488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.